WHO Requests Explanations On Covaxin; To Reconvene On November 3 For Final Review
WHO announced on October 26, that Technical-Advisory-Group (TAG) for Emergency-Use-Listing (EUL) has made the decision that added clarifications from Bharat-Biotech are required before a final EUL risk-benefit assessment for global use of Covaxin can be conducted. WHO stated that TAG “expects to receive these clarifications by the end of this week, and aims to reconvene on November 3”. Covaxin's acceptance by foreign countries is contingent on WHO's approval.